The US Pharmacogenomics Market is experiencing increasing integration of genomic information into healthcare research and clinical decision-making. Hospitals, diagnostic laboratories, and pharmaceutical companies are expanding their pharmacogenomic capabilities. Continued technological development is expected to support broader utilization of genetic testing.

The Pharmacogenomics Market is becoming an increasingly important part of precision medicine as healthcare providers look for ways to select medicines and dosages according to individual genetic characteristics. The Pharmacogenomics Market was valued at US$ 7,087.81 million in 2021 and is projected to reach US$ 14,107.80 million by 2028, expanding at a CAGR of 10.3% from 2021 to 2028. Increasing adoption of personalized medicine, growing availability of genetic testing, advances in sequencing technologies, and greater attention to medication-related adverse reactions are supporting the expansion of pharmacogenomic applications.

Pharmacogenomics studies how a person’s genetic makeup can influence their response to medicines. Genetic differences can affect how quickly a drug is metabolized, how much of it reaches the bloodstream, whether a patient is likely to experience an adverse reaction, or whether a particular therapy is likely to provide a benefit. As genomic information becomes more accessible, pharmacogenomics is increasingly connecting laboratory testing with treatment decisions.

Why Is Pharmacogenomics Becoming More Important?

Traditional prescribing often follows a generalized approach in which patients receive a standard medicine and dose based primarily on their disease, age, weight, medical history, and other clinical characteristics. However, patients can respond differently to the same treatment.

Pharmacogenomic testing provides another layer of information. By identifying specific genetic variants, healthcare professionals can sometimes determine whether a patient is more likely to metabolize a medicine rapidly, slowly, or at an expected rate.

The US Food and Drug Administration (FDA) recognizes that pharmacogenomic information can help identify responders and non-responders, assess potential adverse-event risks, and support genotype-specific dosing. Its drug-labeling database includes pharmacogenomic information across a wide range of therapeutic products.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00007564

What Is Driving the Pharmacogenomics Market?

Several factors are contributing to increasing adoption.

Growing demand for personalized medicine is one of the strongest drivers. Healthcare providers and pharmaceutical companies are increasingly interested in treatment strategies that account for individual biological differences rather than relying solely on population-level responses.

Another factor is the increasing availability of genomic testing. Advances in sequencing and molecular diagnostic technologies have made it easier to identify genetic variants relevant to medication response.

The expansion of biomarker-based drug development is also important. Pharmaceutical companies can use genomic information during clinical development to identify patient populations, investigate treatment response, and potentially improve clinical-trial design.

In addition, growing awareness of adverse drug reactions is encouraging healthcare organizations to consider whether genetic information could improve medication safety in appropriate clinical situations.

How Are Pharmacogenomic Tests Used in Drug Therapy?

Pharmacogenomic testing can provide information about genes involved in drug metabolism, transport, drug targets, and susceptibility to certain adverse reactions.

For example, the FDA identifies CYP2D6, CYP2C19, CYP2C9, HLA-B, DPYD, TPMT, and CYP3A5 among genes or genetic markers associated with information in drug labeling or pharmacogenetic recommendations.

The clinical significance varies considerably between gene-drug combinations.

The FDA’s pharmacogenetic association database includes examples where genetic information can support therapeutic management. For instance, patients carrying the HLA-B*57:01 allele have a higher risk of hypersensitivity to abacavir, and the FDA recommends avoiding the drug in patients who test positive for this allele.

Other associations may influence drug concentrations or potential response without necessarily providing sufficient evidence for routine testing before prescribing. This distinction is important because pharmacogenomics is not a universal test that automatically determines the best medicine for every patient.

Oncology Remains an Important Application Area

Cancer treatment is one of the major areas where genomics and drug therapy increasingly intersect.

Tumor biomarkers can help determine whether particular therapies are appropriate, while inherited genetic information can provide additional insight into how patients may metabolize or tolerate certain medicines.

The FDA’s pharmacogenomic labeling database includes numerous oncology products associated with biomarkers such as EGFR, BRAF, HER2, PIK3CA, ALK, ROS1, mismatch repair, and other molecular characteristics.

This creates opportunities for laboratories and diagnostic companies developing molecular assays that support treatment selection.

The broader movement toward precision oncology is also encouraging pharmaceutical companies to develop therapies alongside biomarker strategies, creating a closer relationship between drug development and genomic diagnostics.

Why Are Clinical Guidelines Critical?

Generating a genetic result is only the beginning. The healthcare system also needs a reliable method for translating that result into an actionable treatment decision.

Clinical pharmacogenetics guidelines play an important role here. The Clinical Pharmacogenetics Implementation Consortium (CPIC) develops evidence-based guidelines intended to help clinicians interpret genetic test results and apply them to medication decisions.

This is particularly important because genetic results can be complex. A test may identify a particular variant, but clinicians need to understand whether that variant changes drug metabolism, efficacy, toxicity, or dosing.

Standardized interpretation can therefore help reduce uncertainty and make pharmacogenomic testing more useful in routine healthcare.

Technology Is Expanding the Competitive Landscape

The development of high-throughput sequencing, molecular diagnostics, bioinformatics, and laboratory automation is creating opportunities across the pharmacogenomics value chain.

Companies are increasingly competing through testing accuracy, sequencing capabilities, turnaround times, interpretation tools, laboratory infrastructure, and integration with clinical systems.

The market includes major healthcare and life sciences companies such as:

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Illumina Inc.
• Myriad Genetics Inc.
• Agilent Technologies Inc.
• Oxford Nanopore Technologies
• Admera Health
• Dynamic DNA Laboratories

These companies operate across areas including molecular diagnostics, sequencing, genomic analysis, genetic testing, laboratory technologies, and precision medicine services.

What Challenges Could Limit Adoption?

Despite its potential, several challenges remain.

One of the most important is clinical implementation. A genetic test must provide information that can actually influence treatment decisions. If test results are difficult to interpret or are not integrated into prescribing workflows, clinical adoption may remain limited.

Evidence quality is another challenge. The FDA explicitly states that the presence of a gene-drug association in its database does not necessarily mean that pharmacogenetic testing should be performed before prescribing. The clinical relevance and strength of evidence differ among individual associations.

Data privacy is also a significant consideration because genetic information is highly personal and can remain relevant throughout an individual’s lifetime.

Other barriers include reimbursement, testing accessibility, healthcare-provider education, interoperability between laboratories and electronic health records, and differences in the representation of populations in genomic research.

How Could Artificial Intelligence Support Pharmacogenomics?

Artificial intelligence could become an important supporting technology as the volume of genomic and clinical information continues to increase.

Machine-learning systems can potentially help researchers analyze large datasets, identify relationships between genetic variants and treatment outcomes, and organize evidence from scientific publications.

Artificial intelligence could also support clinical decision systems by helping connect a patient’s pharmacogenomic profile with relevant drug information and evidence-based recommendations.

However, these applications require careful validation. Automated systems should complement clinical judgment rather than replace it, particularly when evidence surrounding a gene-drug relationship remains uncertain.

What Is the Future of the Pharmacogenomics Market?

The next phase of pharmacogenomics will likely focus less on simply increasing the number of genetic tests and more on making genetic information clinically actionable.

Greater interoperability between laboratories, genomic databases, electronic health records, and clinical decision-support platforms could make test results easier to use across healthcare settings.

The FDA’s continued maintenance and expansion of pharmacogenomic and pharmacogenetic information demonstrates the growing importance of genomic evidence in medication-related decision-making. The agency updated its pharmacogenetic association table in September 2026, adding or revising several gene-drug relationships.

For healthcare providers, the opportunity lies in using validated genomic information where it can meaningfully support treatment decisions. For diagnostic and technology companies, opportunities extend from sequencing and testing to interpretation software and clinical integration.

Also Available in: Korean | German | Japanese | French | Chinese | Italian | Spanish

Related Reports:

Mononucleosis Diagnostic Market Segments and Growth by 2031

Bioprocessing Market Analysis and Opportunities by 2031

About Us

The Insight Partners is a one-stop provider of actionable industry research and intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Food and Beverages, Consumer Goods, and Chemicals and Materials.

Contact Us

Contact Person: Ankit Mathur

Phone: +1-646-491-9876

E-mail : sales@theinsightpartners.com